Fannie Mae, Freddie Mac shares tumble after conservatorship comments
Investing.com -- Viking Therapeutics, Inc. (NASDAQ:VKTX) reported a wider-than-expected second quarter loss on Wednesday, sending shares down 4.2% as investors reacted to the earnings miss despite progress across the company’s obesity drug pipeline.
The clinical-stage biopharmaceutical company posted a second quarter loss of $0.58 per share, missing analyst estimates of $0.45 per share by $0.13. The company did not report revenue figures as it continues to focus on advancing its clinical programs. Viking ended the quarter with a strong cash position of $808 million, which management says provides sufficient runway to support its ongoing development efforts.
"The Viking team achieved significant execution and clinical milestones during the first half of 2025," stated Brian Lian, Ph.D., chief executive officer of Viking. "We recently announced the initiation of the VANQUISH Phase 3 registration program, consisting of two studies: one in patients with obesity and one in patients with obesity and type 2 diabetes."
Viking has made notable progress with its VK2735 program, a dual GLP-1/GIP receptor agonist for obesity treatment. The company recently initiated Phase 3 VANQUISH registration trials and completed enrollment in its Phase 2 VENTURE-Oral Dosing study, with top-line results expected in the second half of 2025. The oral formulation could potentially offer patients an alternative to injectable therapies.
The company is also advancing its amylin agonist program, with plans to submit an Investigational New Drug (IND) application in the fourth quarter of 2025. This program targets the amylin and calcitonin receptors, which play important roles in food intake and metabolic control.
Viking’s Phase 3 VANQUISH program includes two studies targeting approximately 4,500 adults with obesity or who are overweight with co-morbidities, and approximately 1,100 adults with type 2 diabetes who are obese or overweight.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.